Table 2.
Clinical cancer characteristics of the study population overall and stratified by Maryland county (N = 100).
| Total (N = 100) N (%) | Maryland County | |||
|---|---|---|---|---|
| Baltimore City/County (N = 33) N (%) | Prince George's (N = 33) N (%) | Other (N = 34)N (%) | ||
| Stage of breast cancer at diagnosis | ||||
| In situ | 28 (28.0) | 11 (33.3) | 9 (27.3) | 8 (23.5) |
| Stages I-IV | 70 (70.0) | 21 (63.6) | 23 (69.7) | 26 (76.5) |
| Missing | 2 (2.0) | 1 (3.0) | 1 (3.0) | 0 (0.0) |
| Previous breast cancer treatment completed | ||||
| Breast-conserving surgery | 51 (51.0) | 18 (54.5) | 16 (48.5) | 17 (50.0) |
| Mastectomy | 46 (46.0) | 17 (51.5) | 14 (42.4) | 15 (44.1) |
| Radiation | 58 (58.0) | 18 (54.5) | 22 (66.7) | 18 (52.9) |
| Adjuvant chemotherapy | 36 (36.0) | 16 (48.5) | 11 (33.3) | 9 (26.5) |
| Neoadjuvant chemotherapy | 14 (14.0) | 1 (3.0) | 6 (18.2) | 7 (20.6) |
| Hormone or endocrine therapy | 47 (47.0) | 13 (39.4) | 13 (39.4) | 21 (61.8) |
| Targeted drug therapy | 6 (6.0) | 0 (0.0) | 3 (9.1) | 3 (9.1) |
| Immunotherapy or biological therapies | 3 (3.0) | 0 (0.0) | 1 (3.0) | 2 (5.9) |
| Stem cell transplant | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Precision medicine | 1 (1.0) | 0 (0.0) | 0 (0.0) | 1 (2.9) |
| Clinical trial | 4 (4.0) | 1 (3.0) | 1 (3.0) | 2 (5.9) |
| No treatment(s) | 3 (3.0) | 0 (0.0) | 2 (6.1) | 1 (2.9) |
| Current status of cancer treatment | ||||
| Currently undergoing treatment | 22 (22.0) | 3 (9.1) | 9 (27.3) | 10 (29.4) |
| Completed treatment | 69 (69.0) | 26 (78.8) | 22 (66.7) | 21 (61.8) |
| Did not receive treatment | 5 (5.0) | 2 (6.1) | 2 (6.1) | 1 (2.9) |
| Missing | 4 (4.0) | 2 (6.1) | 0 (0.0) | 2 (5.9) |
| Experienced a recurrence | ||||
| No | 80 (80.0) | 25 (75.8) | 27 (81.8) | 28 (82.4) |
| Yes | 19 (19.0) | 8 (24.2) | 5 (15.2) | 6 (17.6) |
| Missing | 1 (1.0) | 0 (0.0) | 1 (3.0) | 0 (0.0) |
| Metastases in breast cancer diagnosis | ||||
| No | 85 (85.0) | 28 (84.8) | 27 (81.8) | 30 (88.2) |
| Yes | 15 (15.0) | 5 (15.2) | 6 (18.2) | 4 (11.8) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Experienced second primary | ||||
| No | 84 (84.0) | 27 (81.8) | 29 (85.3) | 28 (84.8) |
| Yes | 15 (15.0) | 6 (18.2) | 5 (14.7) | 4 (12.1) |
| Missing | 1 (1.0) | 0 (0.0) | 0 (0.0) | 1 (3.0) |
| Experienced any other cancer diagnoses in lifetime | ||||
| No | 85 (85.0) | 27 (81.8) | 27 (81.8) | 31 (91.2) |
| Yes | 15 (15.0) | 6 (18.2) | 6 (18.2) | 3 (8.8) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Completed breast cancer screening measured in the last year | ||||
| No | 22 (22.0) | 13 (39.4) | 3 (9.1) | 6 (17.6) |
| Yes | 77 (77.0) | 20 (60.6) | 29 (87.9) | 28 (82.4) |
| Missing | 1 (1.0) | 0 (0.0) | 1 (3.0) | 0 (0.0) |
| First-degree relatives with breast cancer | ||||
| No | 68 (68.0) | 22 (66.7) | 23 (67.6) | 23 (69.7) |
| Yes | 32 (32.0) | 11 (33.3) | 11 (32.4) | 10 (30.3) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Undergo genetic testing for breast cancer-related genetic mutations | ||||
| No | 40 (40.0) | 18 (54.5) | 11 (32.4) | 11 (33.3) |
| Yes | 60 (60.0) | 15 (45.5) | 23 (67.6) | 22 (66.7) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |